

- **Investment Rational**  
Breakthrough Alpha Radiation Therapy to Fight solid Cancer tumors Being studied globally and advancing towards worldwide regulatory approvals.
- **Business Strategy**  
In US and Japan, initiated FDA multi-center clinical trial. Establishing local manufacturing plant distribution channels. Expanding manufacturing for rapid growth of clinical trials.
- **Core Technology**  
High precision alpha radiation delivered by inserting Radium-224 impregnated seeds into the tumor. When the Radium-224 decays, its daughter atoms recoil and diffuse throughout the tumor, releasing alpha particles along the way. The alpha particles effectively kill cancer cells by creating double-strand DNA breaks. Since its therapeutic range is concentrated to a few millimeters around the seed in the tumor, Alpha DaRT's localized action spares the surrounding healthy tissue.
- **Product Profile/Pipeline**  
Clinical Results has shown promising results. >78% complete response rate with high safety and minimal local and no system toxicity.
- **What's Next?**
  - R&D  
Team of professional from all the range of BioConvergence fields, developing delivery methods for various organs.
  - Preclinical / Clinicals  
Translational research of new indications and combinations with standard treatments followed by clinical program for validating the use in various cancers.
  - Organizational Plans  
New Jerusalem HQ and R&D center with radioactive production line for up to 6000 patients. Adding more sites in the US and Japan.
  - Financial Plans Seasoned healthcare professionals with proven track records. Raised privately \$60M. And recently \$100M in Nasdaq SPAC.
  - Main Service:** In parallel clinical studies in additional indications with unmet need like pancreatic, liver, and Brain cancers.
  - Key Strengths:** patented technology for utilizing alpha particle treatment of solid tumors market potential of billions annually. Experienced management for medical technologies from bench to the market and publicly traded companies.
- **Experience with Israeli Companies:** Working closely with main cancer centers.
- **Key Markets:** unfortunately cancer diseases are spread all over the world with millions of people suffering life risking conditions which many of them have no adequate existing treatment. This makes the whole world relevant for the company's therapeutic technology.